KROS vs. BLTE, TVTX, IRON, IOVA, WVE, EVO, PRAX, AMPH, GLPG, and AAPG
Should you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Belite Bio (BLTE), Travere Therapeutics (TVTX), Disc Medicine (IRON), Iovance Biotherapeutics (IOVA), Wave Life Sciences (WVE), Evotec (EVO), Praxis Precision Medicines (PRAX), Amphastar Pharmaceuticals (AMPH), Galapagos (GLPG), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.
Keros Therapeutics vs.
Keros Therapeutics (NASDAQ:KROS) and Belite Bio (NASDAQ:BLTE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.
Belite Bio has lower revenue, but higher earnings than Keros Therapeutics. Belite Bio is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.
Keros Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.59, indicating that its stock price is 259% less volatile than the S&P 500.
71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 22.9% of Keros Therapeutics shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Keros Therapeutics had 1 more articles in the media than Belite Bio. MarketBeat recorded 2 mentions for Keros Therapeutics and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.50 beat Keros Therapeutics' score of 0.65 indicating that Belite Bio is being referred to more favorably in the news media.
Belite Bio has a net margin of 0.00% compared to Keros Therapeutics' net margin of -27,890.94%. Belite Bio's return on equity of -31.94% beat Keros Therapeutics' return on equity.
Keros Therapeutics presently has a consensus price target of $52.56, suggesting a potential upside of 377.56%. Belite Bio has a consensus price target of $96.33, suggesting a potential upside of 69.01%. Given Keros Therapeutics' higher probable upside, analysts plainly believe Keros Therapeutics is more favorable than Belite Bio.
Keros Therapeutics received 30 more outperform votes than Belite Bio when rated by MarketBeat users. However, 96.88% of users gave Belite Bio an outperform vote while only 69.32% of users gave Keros Therapeutics an outperform vote.
Summary
Keros Therapeutics beats Belite Bio on 9 of the 17 factors compared between the two stocks.
Get Keros Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Keros Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:KROS) was last updated on 2/22/2025 by MarketBeat.com Staff
